These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36531707)

  • 1. Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors.
    Torrente M; Blanco M; Franco F; Garitaonaindia Y; Calvo V; Collazo-Lorduy A; Gutiérrez L; Sánchez JC; González-Del-Alba A; Hernández R; Méndez M; Cantos B; Núñez B; Sousa PAC; Provencio M
    Front Cardiovasc Med; 2022; 9():1062858. PubMed ID: 36531707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
    Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
    Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do.
    Zito C; Manganaro R; Ciappina G; Spagnolo CC; Racanelli V; Santarpia M; Silvestris N; Carerj S
    Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management.
    Zhou YW; Zhu YJ; Wang MN; Xie Y; Chen CY; Zhang T; Xia F; Ding ZY; Liu JY
    Front Pharmacol; 2019; 10():1350. PubMed ID: 31849640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center.
    Waheed N; Fradley MG; DeRemer DL; Mahmoud A; Shah CP; Langaee TY; Lipori GP; March K; Pepine CJ; Cooper-DeHoff RM; Wu Y; Gong Y
    Cardiooncology; 2021 Mar; 7(1):10. PubMed ID: 33736707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors.
    Laenens D; Yu Y; Santens B; Jacobs J; Beuselinck B; Bechter O; Wauters E; Staessen J; Janssens S; Van Aelst L
    J Clin Oncol; 2022 Oct; 40(29):3430-3438. PubMed ID: 35772044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature.
    Agrawal N; Khunger A; Vachhani P; Colvin TA; Hattoum A; Spangenthal E; Curtis AB; Dy GK; Ernstoff MS; Puzanov I
    Case Rep Oncol; 2019; 12(1):260-276. PubMed ID: 31011325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
    Achim A; Liblik K; Gevaert S
    Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
    Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
    J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiotoxicity of Immune Checkpoint Inhibitors.
    Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
    Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated Cardiovascular Toxicities.
    Wu NC; Feng YH; Kuo YH; Chen WY; Wu HC; Huang CT; Wang WC; Kang NW; Shih JY; Chen ZC; Chang WT
    Acta Cardiol Sin; 2022 Jan; 38(1):39-46. PubMed ID: 35068882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis.
    Zhang XT; Ge N; Xiang ZJ; Liu T
    Cancer Cell Int; 2022 Nov; 22(1):363. PubMed ID: 36402980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
    Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
    Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential Cardiotoxicity of Immune Checkpoint Inhibitors.
    Nardi Agmon I; Itzhaki Ben Zadok O; Kornowski R
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients.
    Tajiri K; Sekine I
    Jpn J Clin Oncol; 2022 Jul; 52(7):659-664. PubMed ID: 35348725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular events after the initiation of immune checkpoint inhibitors.
    Suzuki Y; Kaneko H; Tamura Y; Okada A; Fujiu K; Michihata N; Takeda N; Jo T; Morita H; Node K; Yasunaga H; Komuro I
    Heliyon; 2023 May; 9(5):e16373. PubMed ID: 37251893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects.
    Paluri RK; Pulipati Y; Regalla DKR
    Oncol Rev; 2023; 17():11456. PubMed ID: 38045806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis.
    Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
    Eur J Heart Fail; 2021 Oct; 23(10):1739-1747. PubMed ID: 34196077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-Associated Myocarditis.
    Ganatra S; Neilan TG
    Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy.
    Tamura Y; Tamura Y; Yamada K; Taniguchi H; Iwasawa J; Yada H; Kawamura A
    Heart Vessels; 2022 Nov; 37(11):1859-1865. PubMed ID: 35633369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.